CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

BACKGROUND: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy is widely used in peripheral T cell lymphoma (PTCL). Here we conducted a phase 2, multicenter, randomized, controlled trial, comparing the efficacy and safety of CEOP/IVE/GDP alternating regimen wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Ming-Ci, Cheng, Shu, Wang, Xin, Hu, Jian-Da, Song, Yong-Ping, Huang, Yao-Hui, Yan, Zi-Xun, Jiang, Yu-Jie, Fang, Xiao-Sheng, Zheng, Xiao-Yun, Dong, Li-Hua, Ji, Meng-Meng, Wang, Li, Xu, Peng-Peng, Zhao, Wei-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191773/
https://www.ncbi.nlm.nih.gov/pubmed/32349779
http://dx.doi.org/10.1186/s13073-020-00739-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191773/
https://www.ncbi.nlm.nih.gov/pubmed/32349779
http://dx.doi.org/10.1186/s13073-020-00739-0

Ejemplares similares